7.865

4.20% -0.345

Nextcure Inc (NXTC)

Overview News Price History Option Chain Financials Why NXTC Down? Discussions Forecast

Nextcure Inc stock is traded at $7.865, with a volume of 167.61K. It is down -4.20% in the last 24 hours and up +31.30% over the past month. NextCure Inc is a clinical-stage biopharmaceutical company that is focused on advancing inventive medicines that treat cancer patients that do not respond to, or that have disease progression on, current therapies, through the use of targeted therapies including antibody-drug conjugates. The company's product candidates include NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.

Previous Close:

$8.21

Open:

$8.17

24h Volume:

167.61K

Relative Volume:

0.08

Market Cap:

$36.00M

Revenue:

Net Income/Loss:

$-54.66M

P/E Ratio:

-0.4124

EPS:

-19.0729

Net Cash Flow:

$-49.98M

1W Performance:

+14.99%

1M Performance:

+31.30%

6M Performance:

-40.46%

1Y Performance:

+53.76%

1-Day Range:

$7.58

$8.285

1-Week Range:

$6.46

$8.72

52-Week Range:

$1.55

$15.74

Nextcure Inc Stock (NXTC) Company Profile

Name

Nextcure Inc

Sector

Healthcare (1089)

Industry

Biotechnology (604)

Phone

240-399-4900

Address

9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE, MD

Employee

Twitter

@nextcureinc

Next Earnings Date

2026-08-06

Latest SEC Filings

NXTC's Discussions on Twitter

Compare NXTC vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
NXTC Nextcure Inc	7.865	37.58M	0	-54.66M	-49.98M	-19.07
VRTX Vertex Pharmaceuticals Inc	516.25	128.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	806.82	82.72B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	992.77	53.26B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	215.15	43.66B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	362.23	39.31B	5.76B	514.49M	1.10B	4.4813

Nextcure Inc Stock (NXTC) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-07-25	Upgrade	Ladenburg Thalmann	Neutral → Buy
Nov-04-22	Downgrade	Ladenburg Thalmann	Buy → Neutral
Mar-01-22	Initiated	Ladenburg Thalmann	Buy
Mar-05-21	Upgrade	Truist	Hold → Buy
Jan-15-21	Downgrade	BofA Securities	Neutral → Underperform
Jul-16-20	Upgrade	The Benchmark Company	Hold → Buy
Jul-13-20	Downgrade	ROTH Capital	Buy → Neutral
Jul-13-20	Downgrade	SunTrust	Buy → Hold
Jun-01-20	Downgrade	BofA/Merrill	Buy → Neutral
Jun-01-20	Downgrade	The Benchmark Company	Buy → Hold
May-26-20	Initiated	JMP Securities	Mkt Outperform
Mar-24-20	Initiated	The Benchmark Company	Buy
Mar-02-20	Initiated	ROTH Capital	Buy
Jan-13-20	Initiated	SunTrust	Buy
Dec-05-19	Initiated	Needham	Buy
Nov-26-19	Initiated	BTIG Research	Buy
Jul-09-19	Initiated	BofA/Merrill	Buy
Jun-03-19	Initiated	Morgan Stanley	Overweight
Jun-03-19	Initiated	Piper Jaffray	Overweight

View All

Nextcure Inc Stock (NXTC) Latest News

Aug 14, 2026

Ikarian Capital discloses 9.99% NextCure (NXTC) stake including large warrant position - Stock Titan

Aug 14, 2026

NextCure (NXTC) gains 15.8% beneficial owner in ADAR1 Capital and manager - Stock Titan

Aug 14, 2026

Nextcure Stock Price Forecast. Should You Buy NXTC? - StockInvest.us

Aug 14, 2026

NextCure Inc (NASDAQ: NXTC) Stock Price, News & Analysis - Kalkine

Aug 14, 2026

NextCure (NXTC): Squadron funds and partners disclose 1.6% equity stake - Stock Titan

Aug 14, 2026

Aug 13, 2026

Affinity Asset Advisors discloses 6.4% NextCure (NXTC) stake via stock and warrants - Stock Titan

Aug 13, 2026

NextCure stock rating reiterated at Buy by H.C. Wainwright - Investing.com

Aug 13, 2026

Aug 12, 2026

Major Former Stakeholder Makes a Significant Move in NextCure Stock - TipRanks

Aug 12, 2026

Adage Capital files Schedule 13G showing 7.67% NextCure (NXTC) ownership - Stock Titan

Aug 12, 2026

Simcere Zaiming sells $184,800 of NextCure stock - Investing.com

Aug 12, 2026

Simcere Zaiming sells $184,800 of NextCure stock By Investing.com - Investing.com Canada

Aug 12, 2026

Simcere group (NXTC) trims NextCure stake, ends 10% beneficial ownership - Stock Titan

Aug 12, 2026

RTW Biotech's Avere to go public in US in reverse merger with NextCure - London South East

Aug 12, 2026

Aug 11, 2026

RTW Biotech Opportunities (RTWG) Supports Avere Therapeutics’ $820M Capital Raise and NextCure Reverse Merger - Kalkine Media

Aug 11, 2026

NextCure - thepharmaletter.com

Aug 11, 2026

Aug 10, 2026

NextCure (NXTC) plans reverse merger with Avere and $820M financings - Stock Titan

Aug 10, 2026

Xcellon Acquires 40,000 Sq ft Maryland Facility from NextCure to Deliver a cGMP-Ready CRDMO for ADCs - BioBuzz

Aug 10, 2026

Xcellon Biologics Acquires GMP Manufacturing Facility from NextCure, Becoming an End-to-End CRDMO for Next-Generation Bioconjugates and Complex Biologics - The Manila Times

Aug 10, 2026

Avere Therapeutics Announces $500 Million Private Placement to Support Development of Once-Weekly Oral IL-23 Therapy AVR-001 - PR Newswire

Aug 10, 2026

Aug 09, 2026